Compare Stocks: AADI, PRLD, QTTB, and CMPX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$4.60 -0.6%	$4.29	$1.21 ▼ $3.81	$113.61M	0.68	261,100 shs	178,142 shs
CMPX Compass Therapeutics	$2.38 +0.4%	$2.22	$1.61 ▼ $6.88	$428.61M	0.95	2.84 million shs	2.54 million shs
PRLD Prelude Therapeutics	$5.46 +4.0%	$5.06	$0.98 ▼ $6.83	$435.72M	0.97	582,770 shs	400,284 shs
QTTB Q32 Bio	$11.99 -6.3%	$15.04	$1.63 ▼ $23.57	$356.93M	0.21	386,731 shs	851,457 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	-0.65%	-0.43%	+13.02%	+10.84%	+152.75%
CMPX Compass Therapeutics	0.00%	-0.83%	+19.60%	+16.67%	-29.38%
PRLD Prelude Therapeutics	0.00%	-0.18%	+16.67%	+43.31%	+347.54%
QTTB Q32 Bio	0.00%	-20.23%	-25.99%	-8.54%	+601.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$4.60 -0.6%	$4.29	$1.21 ▼ $3.81	$113.61M	0.68	261,100 shs	178,142 shs
CMPX Compass Therapeutics	$2.38 +0.4%	$2.22	$1.61 ▼ $6.88	$428.61M	0.95	2.84 million shs	2.54 million shs
PRLD Prelude Therapeutics	$5.46 +4.0%	$5.06	$0.98 ▼ $6.83	$435.72M	0.97	582,770 shs	400,284 shs
QTTB Q32 Bio	$11.99 -6.3%	$15.04	$1.63 ▼ $23.57	$356.93M	0.21	386,731 shs	851,457 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	-0.65%	-0.43%	+13.02%	+10.84%	+152.75%
CMPX Compass Therapeutics	0.00%	-0.83%	+19.60%	+16.67%	-29.38%
PRLD Prelude Therapeutics	0.00%	-0.18%	+16.67%	+43.31%	+347.54%
QTTB Q32 Bio	0.00%	-20.23%	-25.99%	-8.54%	+601.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	0.00	N/A	N/A	N/A
CMPX Compass Therapeutics	2.88	Moderate Buy	$11.77	394.51% Upside
PRLD Prelude Therapeutics	2.40	Hold	$7.67	40.42% Upside
QTTB Q32 Bio	2.71	Moderate Buy	$31.00	158.55% Upside

Current Analyst Ratings Breakdown

Latest AADI, PRLD, QTTB, and CMPX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	QTTB Q32 Bio	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$34.00
8/21/2026	QTTB Q32 Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/7/2026	QTTB Q32 Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
8/7/2026	CMPX Compass Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
7/29/2026	PRLD Prelude Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/28/2026	QTTB Q32 Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $36.00
7/17/2026	CMPX Compass Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/13/2026	QTTB Q32 Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$20.00 ➝ $40.00
7/1/2026	CMPX Compass Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$5.00

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	4.53	N/A	N/A	$4.29 per share	1.07
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	$0.92 per share	N/A
PRLD Prelude Therapeutics	$12.14M	35.89	N/A	N/A	$1.68 per share	3.25
QTTB Q32 Bio	$53.74M	6.64	$1.52 per share	7.91	$3.56 per share	3.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	N/A
CMPX Compass Therapeutics	-$66.49M	-$0.40	N/A	N/A	N/A	N/A	-38.71%	-34.72%	11/4/2026 (Estimated)
PRLD Prelude Therapeutics	-$99.50M	-$0.73	N/A	N/A	N/A	N/A	-75.35%	-44.39%	11/11/2026 (Estimated)
QTTB Q32 Bio	$29.82M	$3.00	4.00	N/A	N/A	N/A	50.17%	29.49%	11/12/2026 (Estimated)

Latest AADI, PRLD, QTTB, and CMPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	PRLD Prelude Therapeutics	-$0.1967	-$0.14	+$0.0567	-$0.14	$5.70 million	$5.70 million
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A
8/5/2026	Q2 2026	QTTB Q32 Bio	-$0.46	-$0.44	+$0.02	-$0.44	$0.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
CMPX Compass Therapeutics	N/A	11.22	11.22
PRLD Prelude Therapeutics	N/A	4.07	4.07
QTTB Q32 Bio	N/A	20.30	20.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
CMPX Compass Therapeutics	68.43%
PRLD Prelude Therapeutics	79.72%
QTTB Q32 Bio	31.32%

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
CMPX Compass Therapeutics	18.70%
PRLD Prelude Therapeutics	49.20%
QTTB Q32 Bio	34.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	No Data
CMPX Compass Therapeutics	20	180.09 million	146.41 million	Not Optionable
PRLD Prelude Therapeutics	120	79.80 million	40.54 million	Optionable
QTTB Q32 Bio	39	29.77 million	19.51 million	N/A

AADI, PRLD, QTTB, and CMPX Headlines

Recent News About These Companies

Q32 Bio Inc. $QTTB Stock Position Increased by Atlas Venture Life Science Advisors LLC

September 4 at 3:19 AM | marketbeat.com

Q32 Bio to Participate in Upcoming September Investor Conferences

September 1, 2026 | prnewswire.com

Q32 Bio Inc. (NASDAQ:QTTB) Receives Consensus Rating of "Moderate Buy" from Analysts

August 31, 2026 | marketbeat.com

Q32 Bio (NASDAQ:QTTB) Insider Sells 2,798 Shares of Stock

August 28, 2026 | insidertrades.com

Q32 Bio (NASDAQ:QTTB) Insider Sells $46,334.88 in Stock

August 27, 2026 | marketbeat.com

Lee Kalowski Sells 3,972 Shares of Q32 Bio (NASDAQ:QTTB) Stock

August 27, 2026 | marketbeat.com

Insider Selling: Q32 Bio (NASDAQ:QTTB) CEO Sells 9,845 Shares of Stock

August 27, 2026 | marketbeat.com

Q32 Bio: The Efficacy Is Modest, The Valuation Is Not

August 24, 2026 | seekingalpha.com

Q32 Bio Sees Unusually Large Options Volume (NASDAQ:QTTB)

August 21, 2026 | marketbeat.com

Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

August 17, 2026 | zacks.com

Q32 Bio (NASDAQ:QTTB) stock in focus after mid-stage trial data

August 16, 2026 | kalkinemedia.comK

Renaissance Technologies LLC Acquires 107,315 Shares of Q32 Bio Inc. $QTTB

August 14, 2026 | marketbeat.com

HC Wainwright Forecasts Q32 Bio's Q3 Earnings (NASDAQ:QTTB)

August 7, 2026 | marketbeat.com

Q32 Bio tops estimates as alopecia drug advances toward late-stage trials

August 6, 2026 | seekingalpha.com

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 5, 2026 | prnewswire.com

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet

July 31, 2026 | zacks.com

Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice

July 20, 2026 | zacks.com

Q32 Bio: Bempikibart's Progress Keeps Me Bullish

July 17, 2026 | seekingalpha.com

Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

July 15, 2026 | zacks.com

Q32 Bio prices $200M equity raise

July 15, 2026 | msn.com

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

July 14, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI, PRLD, QTTB, and CMPX Company Descriptions

Aadi Bioscience NASDAQ:AADI

$4.60 -0.03 (-0.65%)

As of 09/4/2026

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Compass Therapeutics NASDAQ:CMPX

$2.38 +0.01 (+0.42%)

As of 09/4/2026 04:00 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Prelude Therapeutics NASDAQ:PRLD

$5.46 +0.21 (+4.00%)

As of 09/4/2026 04:00 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Q32 Bio NASDAQ:QTTB

$11.99 -0.81 (-6.33%)

As of 09/4/2026 04:00 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AADI, PRLD, QTTB, and CMPX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AADI, PRLD, QTTB, and CMPX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AADI, PRLD, QTTB, and CMPX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI, PRLD, QTTB, and CMPX Company Descriptions

Aadi Bioscience NASDAQ:AADI

Compass Therapeutics NASDAQ:CMPX

Prelude Therapeutics NASDAQ:PRLD

Q32 Bio NASDAQ:QTTB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AADI, PRLD, QTTB, and CMPX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AADI, PRLD, QTTB, and CMPX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AADI, PRLD, QTTB, and CMPX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI, PRLD, QTTB, and CMPX Company Descriptions

Aadi Bioscience NASDAQ:AADI

Compass Therapeutics NASDAQ:CMPX

Prelude Therapeutics NASDAQ:PRLD

Q32 Bio NASDAQ:QTTB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools